Literature DB >> 21519022

Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy.

James L Rubenstein1, Patrick A Treseler, Paul J Stewart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21519022      PMCID： PMC3675664          DOI： 10.1200/JCO.2011.34.7252

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

Review 1.  Rituximab for intraocular lymphoma.

Authors:  Sujit Itty; Jose S Pulido
Journal:  Retina       Date:  2009-02       Impact factor: 4.256

2.  Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.

Authors:  C Soussain; F Suzan; K Hoang-Xuan; N Cassoux; V Levy; N Azar; C Belanger; E Achour; V Ribrag; S Gerber; J Y Delattre; V Leblond
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.

Authors:  A Berenbom; R M Davila; H-S Lin; J W Harbour
Journal:  Eye (Lond)       Date:  2006-05-26       Impact factor: 3.775

4.  An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

Authors:  T E Witzig; J M Vose; P L Zinzani; C B Reeder; R Buckstein; J A Polikoff; R Bouabdallah; C Haioun; H Tilly; P Guo; D Pietronigro; A L Ervin-Haynes; M S Czuczman
Journal:  Ann Oncol       Date:  2011-01-12       Impact factor: 32.976

5.  High-dose methotrexate for intraocular lymphoma.

Authors:  Tracy T Batchelor; Gina Kolak; Roberto Ciordia; C Stephen Foster; John W Henson
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

Review 6.  Lenalidomide for the treatment of B-cell malignancies.

Authors:  Asher A Chanan-Khan; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

7.  Intraocular use of rituximab.

Authors:  A S Kitzmann; J S Pulido; B G Mohney; K H Baratz; T Grube; R J Marler; M J Donaldson; B P O'Neill; P B Johnston; K M Johnson; L E Dixon; D R Salomao; J D Cameron
Journal:  Eye (Lond)       Date:  2007-04-20       Impact factor: 3.775

8.  Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.

Authors:  S A Grimm; C A McCannel; A M P Omuro; A J M Ferreri; J-Y Blay; E A Neuwelt; T Siegal; T Batchelor; K Jahnke; T N Shenkier; A J Hall; F Graus; U Herrlinger; D Schiff; J Raizer; J Rubenstein; N Laperriere; E Thiel; N Doolittle; F M Iwamoto; L E Abrey
Journal:  Neurology       Date:  2008-10-21       Impact factor: 9.910

9.  Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Authors:  Peter H Wiernik; Izidore S Lossos; Joseph M Tuscano; Glen Justice; Julie M Vose; Craig E Cole; Wendy Lam; Kyle McBride; Kenton Wride; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Thomas M Habermann
Journal:  J Clin Oncol       Date:  2008-07-07       Impact factor: 44.544

10.  Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.

Authors:  S Frenkel; K Hendler; T Siegal; E Shalom; J Pe'er
Journal:  Br J Ophthalmol       Date:  2008-03       Impact factor: 4.638
View more
  14 in total

1.  High-dose chemotherapy and autologous stem cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen.

Authors:  Jeremy S Abramson
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

Review 2.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

4.  Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.

Authors:  Neel K Gupta; Chia-Ching Wang; Gabriel N Mannis; John-Paul J Yu; James L Rubenstein
Journal:  Leuk Lymphoma       Date:  2017-04-10

Review 5.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

6.  Insights from a Case of Vitreoretinal Lymphoma.

Authors:  Bertil E Damato; Gregory J Bever; Armin R Afshar; James L Rubenstein
Journal:  Ocul Oncol Pathol       Date:  2018-04-17

7.  Memory loss during lenalidomide treatment: a report on two cases.

Authors:  Adeline Rollin-Sillaire; Xavier Delbeuck; Marianne Pollet; Marie-Anne Mackowiak; Pierre Lenfant; Marie-Pierre Noel; Thierry Facon; Xavier Leleu; Florence Pasquier; Emilie Le Rhun
Journal:  BMC Pharmacol Toxicol       Date:  2013-08-12       Impact factor: 2.483

8.  Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.

Authors:  Zhimin Li; Yushi Qiu; David Personett; Peng Huang; Brandy Edenfield; Jason Katz; Darius Babusis; Yang Tang; Michael A Shirely; Mehran F Moghaddam; John A Copland; Han W Tun
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

9.  Recent advances in treatment of primary central nervous system lymphoma.

Authors:  Lakshmi Nayak; Tracy T Batchelor
Journal:  Curr Treat Options Oncol       Date:  2013-12

10.  Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.

Authors:  XiaoQin Wu; XinYue Zhang; RenDe Xun; MengSi Liu; Zhen Sun; JianChao Huang
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.